anthracycline + cyclophosphamide

Anthracycline + cyclophosphamide is a standard-of-care chemotherapy combination regimen used in the neoadjuvant and adjuvant treatment of breast cancer. In the specific context of clinical trials conducted by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences (such as NCT06340230), the regimen typically utilizes epirubicin (an anthracycline) and cyclophosphamide (an alkylating agent). Anthracyclines exert their cytotoxic effects by intercalating into DNA and inhibiting topoisomerase II, while cyclophosphamide causes DNA cross-linking. This combination serves as a backbone therapy in studies evaluating the efficacy of adding novel agents, such as the HER2-directed antibody-drug conjugate SHR-A1811 and the PD-L1 inhibitor adebrelimab, for patients with HR-positive, HER2-low early-stage breast cancer.

Other names

AC regimenEC regimenepirubicin + cyclophosphamidedoxorubicin + cyclophosphamideanthracycline and cyclophosphamide